A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
12 Feb 2024: Trial registered, NCT06253494
14 May 2024: Trial started, NCT06253494
The trials
NCT06253494: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
State
Under way
Phase
Phase 1 and Phase 2
People
60 planned
Started
14 May 2024
Primary completion
31 Dec 2026
Arms
Arm 2
Results
None posted
12 Feb 2024: Trial registered
14 May 2024: Trial started
How the status changed
19 Nov 2026: First set: Phase 1 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.